BIOMAT Database Logo BIOMAT Database Logo

Results obtained with the NIVGRIP inactivated influenza vaccine applicable by nasal and/or oral route. 1984

A L Petrescu, and N Cajal

The NIVGRIP inactivated influenza vaccine prepared in the "Stefan S. Nicolau" Institute of Virology has proved its efficacy in the specific prophylaxis of influenza. The vaccine can be administered by nasal and/or oral route and has a very low reactogenicity. Application of the NIVGRIP vaccine results in seroconversion rates of 50-70% and in rises in the levels of local neutralizing antibodies in 75-80% of the vaccines. Numerous epidemiological surveys have ascertained that the protection rate obtained by nasal administration of the NIVGRIP vaccine ranges from 50 to 90%, being comparable with that of other commercially available vaccines. The advantages of the use of an inactivated, whole virus vaccine applicable by nonparenteral routes are discussed.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012140 Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM. Respiratory Diseases,Respiratory System Diseases,Disease, Respiratory System,Disease, Respiratory Tract,Respiratory System Disease,Respiratory Tract Disease
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

A L Petrescu, and N Cajal
[Dynamics of interferon in the rhinopharyngeal secretions of adults vaccinated with the NIVGRIP inactivated influenza vaccine by the nasal route].
January 1986, Virologie,
A L Petrescu, and N Cajal
Bivalent influenza vaccination with inactivated vaccines administered by nasal or oral route.
January 1976, Virologie,
A L Petrescu, and N Cajal
[The humoral and cell-mediated immune response induced by the NIVGRIP inactivated influenza vaccine].
January 1988, Virologie,
A L Petrescu, and N Cajal
Efficiency of the NIVGRIP inactivated influenza vaccine applied by oral route: evaluation in a community of pre-school children in the period 1981-84.
January 1985, Virologie,
A L Petrescu, and N Cajal
[Results obtained with heparin by the oral route].
January 1953, Anales de la Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay,
A L Petrescu, and N Cajal
Dynamics of neutralizing secretory influenza antibodies after nasal administration of the NIVGRIP trivalent influenza vaccine.
January 1985, Virologie,
A L Petrescu, and N Cajal
Nasal application of inactivated influenza vaccine.
October 1988, Acta paediatrica Japonica : Overseas edition,
A L Petrescu, and N Cajal
Effect of the oral administration of NIVGRIP inactivated influenza vaccine on virus carriage in the nasopharynx of children aged 0-5 years.
January 1985, Virologie,
A L Petrescu, and N Cajal
Efficacy of inactivated influenza vaccine delivered by oral administration.
January 1989, Current topics in microbiology and immunology,
A L Petrescu, and N Cajal
Experience of nasal application of inactivated influenza vaccine.
January 1976, Developments in biological standardization,
Copied contents to your clipboard!